Hubei Goto Biopharm Co.Ltd.

Gongtong Pharmaceutical released its 2026 interim report. Total operating revenue was 346 million yuan, and net profit attributable to the parent company was a loss of 32.84 million yuan, an increase in loss of 21.69 million yuan compared with the same period last year. Net cash inflow from operating activities was 22.48 million yuan. The company's asset-liability ratio was 69.96%, gross margin was 14.08%, ROE was negative 4.13%, and diluted earnings per share was negative 0.29 yuan. The number of shareholders was 11,500, and the top ten shareholders held 54.78% of the total share capital.

Gongtong Pharmaceutical released its 2026 interim report. Operating revenue was 346 million yuan, up 14.5 percent year on year. Net profit attributable to the parent swung from a loss of 11.15 million yuan in the same period last year to a loss of 32.84 million yuan, with the loss widening further. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 10.22 million yuan a year earlier to a loss of 32.67 million yuan, also widening. Operating cash flow was 22.48 million yuan, up 488.0 percent year on year. Earnings per share were negative 0.29 yuan. In the second quarter, operating revenue was 184 million yuan, up 13.0 percent year on year. Net profit attributable to the parent swung from a loss of 12.23 million yuan a year earlier to a loss of 36.04 million yuan, with the loss widening further. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 11.56 million yuan to a loss of 35.96 million yuan, also widening. Earnings per share were negative 0.3126 yuan. As of the end of the second quarter, total assets were 2.904 billion yuan, up 1.9 percent from the end of the previous year. Net assets attributable to the parent were 795 million yuan, down 3.8 percent from the end of the previous year. In the 2026 interim report, the company noted that its main business operations had not undergone major changes during the reporting period. It continued to focus on the research, development, production and sales of steroid drug raw materials, with main products including starting materials and intermediates required for steroid drug production, and market share for multiple products remained among the industry leaders. In addition, the company's full-industry-chain strategic layout is still advancing steadily, its operating model remains stable, and management is optimistic about future market development.